{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:56:04Z","timestamp":1787273764801,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04090-x","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T11:24:16Z","timestamp":1762169056000},"page":"1422-1430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adjuvant nivolumab vs pembrolizumab in stage IIB\/IIC melanoma: a reinforcement learning-based simulation study"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3994-815X","authenticated-orcid":false,"given":"Perihan","family":"Perkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahriye Tu\u011fba","family":"K\u00f6\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"1","key":"4090_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"4090_CR2","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1001\/jamadermatol.2023.3256","volume":"159","author":"NM Helvind","year":"2023","unstructured":"Helvind NM, Brinch-M\u00f8ller Weitemeyer M, Chakera AH, Friis K, Drzewiecki KT, Schmidt G, et al. Stage-specific risk of recurrence and death from Melanoma in Denmark, 2008\u20132021: a national observational cohort study of 25,720 patients with stage IA to IV melanoma. JAMA Dermatol. 2023;159(11):1213\u201322. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3256.","journal-title":"JAMA Dermatol"},{"issue":"19","key":"4090_CR3","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1709030.","journal-title":"N Engl J Med"},{"issue":"19","key":"4090_CR4","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801. https:\/\/doi.org\/10.1056\/NEJMoa1802357.","journal-title":"N Engl J Med"},{"issue":"21","key":"4090_CR5","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1056\/NEJMoa2118314","volume":"386","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz A, Chiarion-Sileni V, et al. Pembrolizumab versus placebo as adjuvant therapy for resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. N Engl J Med. 2022;386(21):1951\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2118314.","journal-title":"N Engl J Med"},{"issue":"23","key":"4090_CR6","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa2304086","volume":"389","author":"GV Long","year":"2023","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, et al. Adjuvant nivolumab for stage IIB or IIC melanoma. N Engl J Med. 2023;389(23):2119\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2304086.","journal-title":"N Engl J Med"},{"key":"4090_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2020.105443","volume":"193","author":"ZA Ebrahimi","year":"2020","unstructured":"Ebrahimi ZA, Shahabi HS, Soltani M. Reinforcement learning for optimal scheduling of glioblastoma treatment with temozolomide. Comput Methods Programs Biomed. 2020;193:105443. https:\/\/doi.org\/10.1016\/j.cmpb.2020.105443.","journal-title":"Comput Methods Programs Biomed"},{"issue":"6","key":"4090_CR8","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1002\/mp.14114","volume":"47","author":"J Shen","year":"2020","unstructured":"Shen J, Nguyen D, Chen L, Jiang S, Dong B, Moore KL, et al. Operating a treatment planning system using a deep-reinforcement learning-based virtual treatment planner for prostate cancer intensity-modulated radiation therapy treatment planning. J Med Phys. 2020;47(6):2329\u201336. https:\/\/doi.org\/10.1002\/mp.14114.","journal-title":"J Med Phys"},{"issue":"18","key":"4090_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184624","volume":"13","author":"JN Eckardt","year":"2021","unstructured":"Eckardt JN, Wendt K, Bornh\u00e4user M, Middeke JM. Reinforcement learning for precision oncology. Cancers (Basel). 2021;13(18):4624. https:\/\/doi.org\/10.3390\/cancers13184624.","journal-title":"Cancers (Basel)"},{"key":"4090_CR10","unstructured":"Google Colab. https:\/\/colab.research.google.com\/. Accessed 13 Mar 2025."},{"issue":"6","key":"4090_CR11","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0197-2456(03)00072-2","volume":"24","author":"KJ Carroll","year":"2003","unstructured":"Carroll KJ. On the use and utility of the Weibull model in the analysis of survival data. Control Clin Trials. 2003;24(6):682\u2013701. https:\/\/doi.org\/10.1016\/S0197-2456(03)00072-2.","journal-title":"Control Clin Trials"},{"issue":"22","key":"4090_CR12","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1200\/JCO.2000.18.22.3782","volume":"18","author":"J Manola","year":"2000","unstructured":"Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000;18(22):3782\u201393. https:\/\/doi.org\/10.1200\/JCO.2000.18.22.3782.","journal-title":"J Clin Oncol"},{"key":"4090_CR13","volume-title":"Reinforcement learning: an introduction","author":"RS Sutton","year":"2018","unstructured":"Sutton RS, Barto AG. Reinforcement learning: an introduction. 2nd ed. Cambridge: MIT Press; 2018.","edition":"2"},{"issue":"1","key":"4090_CR14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1186\/s12885-024-12985-1","volume":"24","author":"H\u015e Bozcuk","year":"2024","unstructured":"Bozcuk H\u015e, Arta\u00e7 M. A simulated trial with reinforcement learning for the efficacy of irinotecan and ifosfamide versus topotecan in relapsed, extensive stage small cell lung cancer. BMC Cancer. 2024;24(1):1207. https:\/\/doi.org\/10.1186\/s12885-024-12985-1.","journal-title":"BMC Cancer"},{"issue":"11","key":"4090_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pdig.0000651","volume":"3","author":"JL Cross","year":"2024","unstructured":"Cross JL, Choma MA, Onofrey JA. Bias in medical AI: implications for clinical decision-making. PLoS Digit Health. 2024;3(11):e0000651. https:\/\/doi.org\/10.1371\/journal.pdig.0000651.","journal-title":"PLoS Digit Health"},{"issue":"2","key":"4090_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311. https:\/\/doi.org\/10.1177\/0272989X17725740.","journal-title":"Med Decis Making"},{"key":"4090_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-publhealth-031811-124610","volume":"33","author":"HC Sox","year":"2012","unstructured":"Sox HC, Goodman SN. The methods of comparative effectiveness research. Annu Rev Public Health. 2012;33:425\u201345. https:\/\/doi.org\/10.1146\/annurev-publhealth-031811-124610.","journal-title":"Annu Rev Public Health"},{"key":"4090_CR18","unstructured":"European Society for Medical Oncology (ESMO). Cutaneous melanoma: management of local\/locoregional disease (Pt1b\u2013Pt4b cN0 cM0). ESMO Living Guidelines. https:\/\/www.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-cutaneous-melanoma\/management-of-local-locoregional-disease\/pt1b-pt4b-cn0-cm0-melanoma. Accessed 12 Aug 2025."},{"issue":"3","key":"4090_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/096228020101000303","volume":"10","author":"J Benichou","year":"2001","unstructured":"Benichou J. A review of adjusted estimators of attributable risk. Stat Methods Med Res. 2001;10(3):195\u2013216. https:\/\/doi.org\/10.1177\/096228020101000303.","journal-title":"Stat Methods Med Res"},{"key":"4090_CR20","volume-title":"Modern epidemiology","author":"KJ Rothman","year":"2021","unstructured":"Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 4th ed. Philadelphia: Wolters Kluwer; 2021.","edition":"4"},{"key":"4090_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00822","volume":"9","author":"E Ter Veer","year":"2019","unstructured":"Ter Veer E, van Oijen MGH, van Laarhoven HWM. The use of (network) meta-analysis in clinical oncology. Front Oncol. 2019;9:822. https:\/\/doi.org\/10.3389\/fonc.2019.00822.","journal-title":"Front Oncol"},{"key":"4090_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115371","volume":"220","author":"JM Kirkwood","year":"2025","unstructured":"Kirkwood JM, Mohr P, Hoeller C, Grob JJ, Del Vecchio M, Lord-Bessen J, et al. Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB\/C melanoma in the randomized phase 3 CheckMate 76K trial. Eur J Cancer. 2025;220:115371. https:\/\/doi.org\/10.1016\/j.ejca.2025.115371.","journal-title":"Eur J Cancer"},{"issue":"2","key":"4090_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368. https:\/\/doi.org\/10.1056\/NEJMra1703481.","journal-title":"N Engl J Med"},{"issue":"10","key":"4090_CR24","doi-asserted-by":"publisher","first-page":"e537","DOI":"10.1016\/S2589-7500(20)30218-1","volume":"2","author":"X Liu","year":"2020","unstructured":"Liu X, Cruz Rivera S, Moher D, Calvert MJ, Denniston AK, SPIRIT-AI and CONSORT-AI Working Group. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. Lancet Digit Health. 2020;2(10):e537\u201348. https:\/\/doi.org\/10.1016\/S2589-7500(20)30218-1.","journal-title":"Lancet Digit Health"},{"issue":"1","key":"4090_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1186\/s13063-022-06515-2","volume":"23","author":"H Lynggaard","year":"2022","unstructured":"Lynggaard H, Bell J, L\u00f6sch C, Besseghir A, Rantell K, Schoder V, et al. Principles and recommendations for incorporating estimands into clinical study protocol templates. Trials. 2022;23(1):685. https:\/\/doi.org\/10.1186\/s13063-022-06515-2.","journal-title":"Trials"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04090-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04090-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04090-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:05:11Z","timestamp":1774415111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04090-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4090"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04090-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted entirely using simulated patient data; no real patient information was accessed or analyzed. Therefore, approval from an institutional review board and informed consent were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"This study did not involve human participants or the use of individual patient data. The analysis was based on a reinforcement learning simulation model using aggregated outcomes from previously published clinical trials. Therefore, informed consent was not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}